FDA accepted Protagonist Therapeutics’ New Drug Application for rusfertide and granted the drug Priority Review on March 2 2026. The decision places rusfertide on a fast‑track path to U.S. approval, with a Prescription Drug User Fee Act goal date in the third quarter of 2026.
The acceptance follows Phase 3 VERIFY data that met primary and key secondary endpoints, showing significant reductions in phlebotomy frequency and improved patient‑reported outcomes. The data support the drug’s clinical value and reinforce Protagonist’s platform strength.
The regulatory approval would unlock milestone payments and future royalties under the company’s partnership with Takeda. Protagonist’s cash position of $646 million as of December 31 2025 provides the runway to pursue commercialization while the company plans to opt out of the 50:50 U.S. profit‑sharing arrangement with Takeda during a 90‑day window in Q2 2026, positioning it to capture greater economics from rusfertide.
Protagonist’s recent financial performance has shifted from net income to net losses, with FY 2025 revenue falling to $46.0 million from $434.4 million in FY 2024, largely due to lower milestone payments and higher R&D expenses. The company’s cash reserves mitigate short‑term headwinds and support continued investment in its pipeline.
President and CEO Dinesh V. Patel said, "We are very pleased with the FDA granting rusfertide Priority Review and look forward to its potential approval in 2026." He also noted, "We see the next 12 to 24 months as a period of significant growth and value creation for Protagonist." R&D president Andy Plump added, "The FDA's acceptance of our NDA brings us closer to potentially offering a first‑in‑class therapy that could meaningfully improve clinical outcomes and quality of life."
The milestone strengthens Protagonist’s competitive position in a market with limited treatment options and positions the company to capitalize on its first‑in‑class platform, while the opt‑out strategy signals confidence in the drug’s commercial potential and a desire to retain greater control over future revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.